Seladelpar for Treatment of PBC

Key Takeaways

• Seladelpar demonstrates sustained efficacy in improving liver biochemistry and symptom relief in primary biliary cholangitis (PBC) over long-term use.
• The drug modulates lipid metabolism and inflammation, crucial mechanisms in managing PBC, enhancing its therapeutic potential.
• Seladelpar maintains a favorable safety profile with minimal adverse effects, supporting its viability as an alternative treatment for PBC.
• Long-term data reinforce seladelpar's role in addressing unmet clinical needs in PBC, offering a promising option beyond existing therapies.